Unseen Upside: Investments Beyond Their Returns Cambridge Associates

Artificial intelligence is transforming healthcare, unleashing new investment opportunities. From cancer screening to drug discovery, AI promises to augment clinical decision-making and improve care. We’ll explore the surging ecosystem of medical AI innovations, from the emerging tech landscape to practical deployment. But what are the challenges facing real-world implementation? Which applications show the most promise? Join us as we investigate how artificial intelligence can change healthcare for the better while examining what it will take to do it well. Guests include:

Bob Nelsen, Co-Founder and Managing Director at Arch Venture Partners

Daphne Koller, Founder and CEO at insitro

David Baker, Ph.D., Director at the Institute for Protein Design and Professor of Biochemistry at University of Washington

Theresa Hajer, Partner and Managing Director of Venture Capital Research at Cambridge Associates
Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Autoimmune diseases like lupus impact over 5 million patients globally, but treatment options remain limited. Now, decoding the once mysterious "dark genome" could bring new therapies. Over 90% of our DNA was once considered "junk"—but we’ve learned this dark matter regulates gene expression and human disease. This episode takes you to the pioneers who are unlocking the dark genome's potential to correct root causes of complex conditions like lupus. We'll chat with those illuminating this uncharted territory and developing novel approaches. Guests include:

Rosana Kapeller, M.D., Ph.D., Co-Founder, President, & CEO at Rome Therapeutics

Steve Kafka, General Partner at S32

Keri Mastrogiacomo, mother of a Lupus patient

Katherine Cavanagh, Associate Investment Director at Cambridge Associates 
Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Obesity is a global health crisis, with over 650 million adults affected worldwide. This drives massive economic and disease burdens. Yet new treatment options like GLP-1 drugs offer hope. This episode analyzes the investment landscape and future of obesity therapeutics, focusing on transformational GLP-1 drugs like Ozempic that curb appetite. Join us as we investigate the promise and challenges of emerging anti-obesity drugs, learn about one patient’s journey taking them, and discover what the future of weight loss medicine could look like. You'll hear from leaders in the space as well as a current patient taking these medications. Guests include:

Rod Wong, Founder, Managing Partner, and Chief Investment Officer at RTW Investments

Raymond Stevens, Ph.D., Chief Executive Officer at Structure Therapeutics

Dean Dimizas, Partner and Managing Director at Cambridge Associates

Kathleen Mikaelian, Patient
Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Precision oncology represents an exciting shift in cancer treatment from a one-size-fits-all approach to personalized care based on each patient's unique cancer and molecular makeup. In this episode, we'll explore how precision oncology is transforming the landscape of cancer care and improving outcomes at leading hospitals like St. Jude Children’s Research Hospital. We'll discuss the latest precision diagnostic technologies enabling doctors to analyze a tumor's molecular profile and match targeted therapies to save lives. Join us as we investigate the promise of precision medicine to make cancer treatment more effective and more equitable. Guests include:

Rick Shadyac, President and CEO at ALSAC, the fundraising and awareness organization for St. Jude Children’s Research Hospital, a Cambridge Associates client

Matt Gevaert, Co-Founder and Board Member at Kiyatec

Jason Robart, Co-Founder & Managing Partner at Seae Ventures

Jeff Blazek, Partner and Head of the Northeast & Midwest Endowment & Foundation Practice at Cambridge Associates, who works with ALSAC/St. Jude as one of his clients, in partnership with Anurag Pandit, CIO of ALSAC/SJCRH, and the Investment Department.
Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Thanks to medical advances, we're living longer lives but with that comes rising rates of Alzheimer's disease. Currently 6 million Americans have Alzheimer's, and that could triple by 2050. This episode explores emerging innovations offering hope against neurodegenerative diseases. We'll discuss promising new drugs that could slow cognitive decline and the strides scientists are making towards understanding causes and developing therapies—and how these breakthroughs are giving hope to one family fighting to save their mom. Episode two explores the history of Alzheimer’s, its current challenges, and the promising therapies made possible by innovation and investment. You’ll hear from:

Dr. Asa Abeliovich, Neurologist, Molecular Geneticist, and Founder and CEO at Leal Therapeutics

Carl Gordon, Managing Partner and Head of Global Private Equity at OrbiMed

Ham Lee, Co-Head of the Healthcare Practice at Cambridge Associates

Randi Casciano, Director of Global Public Relations at Cambridge Associates
Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

The mental health crisis is growing, especially among Gen Z (91% report anxiety or depression). This episode explores innovations in mental healthcare access, new therapeutic approaches for young people and families, and how hospitals are striking creative partnerships to tackle this emergency. Tune in to learn what’s working and showing promise in mental healthcare, glimpses of what the future could look like, and where persistent gaps remain. Hear from leaders Melody Dickerson (VHC Health); Emily Melton (Threshold Ventures); Naomi Allen (Brightline); and Bridget Sproles (Cambridge Associates).